May - 2017

AK and miltefosine

AK and miltefosine

Three weeks after treatment with oral miltefosine offers promising hope for patients with AK. Miltefosine is not yet approved for AK but has received orphan drug designation.

Featured Posts

CDC Video showing N.Fowleri

CDC Video showing N.Fowleri

AK and miltefosine

AK and miltefosine

4th Patient in the USA to survive the deadly Amoeba Parasite

4th Patient in the USA to survive the deadly Amoeba Parasite

Colombia: Leishmaniasis outbreak affects 80 in Norte de Santander

Colombia: Leishmaniasis outbreak affects 80 in Norte de Santander

Recent Posts

Archive

Search By Tags

Follow Us

Impavido® (miltefosine) is an FDA-approved treatment for cutaneous, mucosal and visceral leishmaniasis in patients 12 years of age and older. PLEASE SEE FULL PRESCRIBING INFO